A word about BioMedCentral

Some of you may be wondering why The Scientist is today publishing a linkurl:news story;http://www.the-scientist.com/news/display/23352/ that on the face of it seems quite critical of BioMedCentral, our sister company. It's a fair question, and one with a simple answer: We are commited to covering significant developments, in science publishing and elsewhere, that are likely to be of interest to our readers, irrespective of the source of the story. This particular article is a test of the edit

Written byRichard Gallagher
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Some of you may be wondering why The Scientist is today publishing a linkurl:news story;http://www.the-scientist.com/news/display/23352/ that on the face of it seems quite critical of BioMedCentral, our sister company. It's a fair question, and one with a simple answer: We are commited to covering significant developments, in science publishing and elsewhere, that are likely to be of interest to our readers, irrespective of the source of the story. This particular article is a test of the editorial independence of The Scientist, and it is a test that has been passed. The co-owner of The Scientist, who also owns BioMedCentral, has not tried to influence the story in any way. I believe in open access, and the editorial position of The Scientist is to support its development. BioMedCentral and the editors of the independent journals that they publish are passionate about open access. Together they are blazing a new trail in publishing, and inevitably this will result in some conflict. Transparency is needed in working out these growing pains. Sweeping issues like the ones raised in the story under the rug would be far more damaging in the long run. Incidentally, we're working on a feature on the state of science publishing, to be published in late summer.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies